Atea/$AVIR
1D1W1MYTD1Y5YMAX
About Atea
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
- Ticker
- $AVIR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 55
- Headquarters
- Boston, United States
- Website
- ateapharma.com
Atea Metrics
BasicAdvanced
$467M
-
-$2.10
0.27
-
Price and volume
Market cap
$467M
Beta
0.27
52-week high
$6.45
52-week low
$2.78
Average daily volume
320K
Financial strength
Current ratio
8.131
Quick ratio
7.803
Total debt to equity
0.208
Profitability
EBITDA (TTM)
-181.702
Effective tax rate (TTM)
3.78%
Management effectiveness
Return on assets (TTM)
-36.72%
Return on equity (TTM)
-58.14%
Valuation
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
-3.018
Free cash flow yield (TTM)
-33.13%
Free cash flow per share (TTM)
-1.928
Growth
Earnings per share change (TTM)
30.03%
3-year earnings per share growth (CAGR)
18.05%
What the Analysts think about Atea
Analyst ratings (Buy, Hold, Sell) for Atea stock.
Atea Financial Performance
Revenues and expenses
Atea Earnings Performance
Company profitability
Atea News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.